Replay of the Aprea Therapeutics Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor  Watch here

Meet the Innovators Behind Aprea

A world-class team of precision oncology leaders.

Aprea’s executive management team, Board of Directors and scientific founders are unified by their dedication to developing groundbreaking, precision therapeutics for patients with genetically defined cancers. Our team’s exceptional qualifications and deep expertise have accelerated Aprea’s mission and continue to fuel its growth as a leader in DDR-targeted therapeutics.

Oren Gilad, Ph.D.

President and Chief Executive Officer

Oren Gilad, Ph.D., has served as Chief Executive Officer of Aprea Therapeutics since July 2022 and as President and a member of its Board of Directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics. Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities. Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR pathway in cancer development and treatment. Dr. Gilad earned his doctorate from the University of California at Davis and his B.S. from the Hebrew University, Jerusalem, Israel.

John P. Hamill, CPA

Senior Vice President and Chief Financial Officer

John joined Aprea in January 2023 from Windtree Therapeutics where he served as Senior Vice President and Chief Financial Officer since 2020. He brings more than 30 years of financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. He brings broad-based experience in financial, administrative, information technology, and facility functions, in addition to successfully completing IPO and follow-on offerings for several pharmaceutical companies. John has also recently provided consulting services to various life science companies, headed up finance at Trevena, Inc., where he was instrumental in successfully raising equity; NephroGenex, Inc., where he actively led the IPO and subsequent financial restructuring and sale of the company; Savient Pharmaceuticals, where he led a sale process resulting in $120 million in proceeds; and PharmaNet where he successfully completed its sale for approximately $250 million, which then became known as PharmaNet Development Group, where he directed financial and administrative operations for the company. John received a B.S. in Accounting and Business and Computer Science from DeSales University and is a certified public accountant.

Nadeem Q. Mirza, M.D., M.P.H.

Chief Medical Officer

Nadeem Q. Mirza, M.D., M.P.H. has served as Senior Medical Advisor to Aprea since February 2023, and was appointed Chief Medical Officer in May 2024. Dr. Mirza brings over 30 years of clinical and developmental experience in solid tumors and hematologic malignancies. He currently serves as Senior Vice President, Clinical Development at Salarius Pharmaceuticals and previously served as Chief Medical Advisor at TRIGR Therapeutics developing bispecific antibodies. Prior to that, Dr. Mirza served as Senior Vice President, Corporate Medical Affairs at Verastem Oncology where he oversaw the launch of Copiktra®. Prior to Verastem, he served as Global Head Hematology and Solid Tumors at Abbvie Oncology where he oversaw the global launch of Venclexta®. Before Abbvie, he was Vice President, Head of Oncology, North America Medical Affairs at Sanofi Oncology where he was responsible for medical affairs programs to support 12 products across several oncology indications. Dr. Mirza has also held leadership roles in medical affairs and clinical development at Genzyme/Sanofi, Onyx Pharmaceuticals, Abraxis Oncology and Berlex Oncology. He holds an M.P.H. from the University of Texas at Houston, and earned his M.D. from the University of Punjab.

Brian Wiley

Senior Vice President of Corporate Development & Strategy

Brian Wiley joined Aprea as Senior Vice President of Corporate Development & Strategy in November 2023. Brian has over 30 years of experience in the biopharmaceutical industry, with over 25 years dedicated to oncology. His experience as a senior BD executive includes numerous licensing transactions, collaborations, M&A, as well as public and private financings. His commercialization experience includes multiple product launches in oncology. Brian has been a major contributor to licensing and M&A transactions exceeding $5 billion and financings in excess of $150 million. Brian is the Principal and Founder of Boston BioConsulting, LLC, a consulting firm that specializes in business development and corporate strategy for the biopharmaceutical industry. Prior to founding Boston BioConsulting, Brian served as Chief Commercial Officer and Head of Business Development at NewLink Genetics. Brian also served in various leadership and management roles at Celgene, Gloucester Pharmaceuticals, Millennium and Aventis. Brian has a marketing degree from the Pennsylvania State University.

Mike Carleton, Ph.D.

Translational Medicine Advisor

Dr. Carleton joins Aprea with over 20 years of experience in the pharmaceutical/biotech industry where he has held leadership roles in preclinical and clinical drug development. He most recently served as Vice President of Translational Medicine at Inipharm where the team developed an inhibitor to the oxidoreductase HSD17B13 for treatment of liver disease. Prior to that, he was Vice President of Translation Medicine at Mavupharma until Abbvie’s acquisition of Mavu and its ENPP1 inhibitor program. As Director of Translational Medicine at Bristol Myers Squibb, Dr. Carleton led clinical oncology biomarker development for the anti-CSF1R (Cabiralizumab) and anti-IL8 (BMS-986253) programs for which his team established elevated serum IL-8 is associated with reduced clinical benefit to immune checkpoint blockade. Dr. Carleton also led research groups at Presage Biosciences, Matrix Genetics, and Rosetta Inpharmatics, a fully-owned subsidiary of Merck. Within the Merck oncology franchise, Dr. Carleton was the biomarker lead for Merck’s WEE1 inhibitor (MK-1775) and its PARP inhibitor programs prior to their out licensing to AstraZeneca (AZD1775, Adavosertib) and Tesaro (Niraparib). Dr. Carleton obtained his Ph.D. in microbiology from the University of Texas at Austin, was a CRI postdoctoral fellow, Arthritis Young Investigator, and currently serves part-time as Senior Scientific Director at The Mark Foundation for Cancer Research.

Ze’ev Weiss, CPA, B.Sc.

Chief Business Advisor

Ze’ev Weiss, CPA, B.S., has served as Chief Business Advisor for Aprea since May 2022. Ze’ev brings over 20 years of broad and extensive biopharmaceuticals industry experience in strategic, operational, and corporate development in the emerging and established healthcare industry. He previously served as Chief Business Officer of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. Previously, Ze’ev served as the CEO of a clinical-stage biopharmaceutical company, leading it through its IPO on the NASDAQ as well as multiple collaboration agreements with leading, global pharmaceutical companies. Prior to that experience, Ze’ev was Head of Life Sciences Strategic Consulting at PricewaterhouseCoopers, Israel. Ze’ev holds a B.A in accounting and is a certified public accountant. He also earned a B.S. in Biology and has completed M.S. in Neuro-Biochemistry studies from Tel Aviv University, Israel.